



Lab resource: Stem Cell Line

## Generation and characterization of a human iPSC line (UAMi004-A) from a patient with propionic acidemia due to defects in the *PCCB* gene

Arístides López-Márquez<sup>a</sup>, Esmeralda Alonso-Barroso<sup>a,b,c,d</sup>, Gema Cerro-Tello<sup>a</sup>, Irene Bravo-Alonso<sup>a,b,c,d</sup>, Laura Arribas-Carreira<sup>a,b,c,d</sup>, Álvaro Briso-Montiano<sup>a,b,c,d</sup>, Rosa Navarrete<sup>b,c,d</sup>, Celia Pérez-Cerdá<sup>b,c,d</sup>, Magdalena Ugarte<sup>b,c,d</sup>, Belén Pérez<sup>a,b,c,d</sup>, Lourdes R. Desviat<sup>a,b,c,d</sup>, Eva Richard<sup>a,b,c,d,\*</sup>

<sup>a</sup> Centro de Biología Molecular Severo Ochoa UAM-CSIC, Universidad Autónoma de Madrid, Madrid, Spain

<sup>b</sup> Centro de Diagnóstico de Enfermedades Moleculares (CEDEM), Madrid, Spain

<sup>c</sup> Centro de Investigación Biomédica en Red de Enfermedades Raras (CIBERER), ISCIII, Madrid, Spain

<sup>d</sup> Instituto de Investigación Sanitaria Hospital La Paz (IdiPaz), ISCIII, Madrid, Spain

### ABSTRACT

A human induced pluripotent stem cell (iPSC) line was generated from fibroblasts of a patient with propionic acidemia that has a homozygous mutation (c.1218\_1231del14ins12 (p.G407 fs)) in the *PCCB* gene. Reprogramming factors *OCT3/4*, *SOX2*, *KLF4* and *c-MYC* were delivered using a non-integrative method based on the Sendai virus. Once established, iPSCs have shown full pluripotency, differentiation capacity and genetic stability. The generated iPSC line represents a useful tool to study the pathomechanisms underlying the deficiency.

Resource table.		Inducible/constitutive system	Non applicable
Unique stem cell lines identifier	UAMi004-A	Date archived/stock date	March 2019
Alternative name of stem cell line	PCCB10-FIPS4F-1	Cell line repository/bank	Spanish National Bank of Cell Lines <a href="http://www.isciii.es/ISCIII/es/contenidos/fd-el-instituto/fd-organizacion/fd-estructura-directiva/fd-subdireccion-general-investigacion-terapia-celular-medicina-regenerativa/fd-centros-unidades/fd-banco-nacional-lineas-celulares/fd-lineas-celulares-disponibles/lineas-de-celulas-iPSC.shtml">http://www.isciii.es/ISCIII/es/contenidos/fd-el-instituto/fd-organizacion/fd-estructura-directiva/fd-subdireccion-general-investigacion-terapia-celular-medicina-regenerativa/fd-centros-unidades/fd-banco-nacional-lineas-celulares/fd-lineas-celulares-disponibles/lineas-de-celulas-iPSC.shtml</a>
Institution	Centro de Biología Molecular Severo Ochoa UAM-CSIC, Universidad Autónoma de Madrid, CIBERER, IDIPaz, Madrid, Spain.	Ethical approval	Patient informed consent obtained. Ethics Review Board-competent authority approval obtained (CEI 71-1278)
Contact information of distributor	Eva Richard, <a href="mailto:erichard@cbm.csic.es">erichard@cbm.csic.es</a>		
Type of cell line	iPSC		
Origin	Human		
Additional origin info	Age: 30 Sex: Female Ethnicity if known: Caucasian		
Cell Source	Fibroblasts		
Clonality	Clonal		
Method of reprogramming	Sendai Virus		
Genetic modification	Yes		
Type of modification	Hereditary		
Associated disease	Propionic acidemia		
Gene/locus	<i>PCCB</i> / 3q22		
Method of modification	Non applicable		
Name of transgene or resistance	Non applicable		

### 1. Resource utility

The pathophysiology of propionic acidemia is not completely understood and its treatment currently is not satisfactory. In order to investigate underlying cellular pathological mechanisms and to test potential therapeutic compounds, we have established an iPSC line with a homozygous mutation in the *PCCB* gene.

### 2. Resource details

Propionic acidemia (PA, MIM#606054, ORPHA:35) is one of the most frequent life-threatening organic acidemias, caused by mutations

\* Corresponding author at: Centro de Biología Molecular Severo Ochoa UAM-CSIC, Nicolás Cabrera 1, Universidad Autónoma Madrid, 28049 Madrid, Spain.  
E-mail address: [erichard@cbm.csic.es](mailto:erichard@cbm.csic.es) (E. Richard).

<https://doi.org/10.1016/j.scr.2019.101469>

Received 23 April 2019; Received in revised form 16 May 2019; Accepted 20 May 2019

Available online 22 May 2019

1873-5061/ © 2019 Published by Elsevier B.V. This is an open access article under the CC BY-NC-ND license (<http://creativecommons.org/licenses/by-nc-nd/4.0/>).




Fig. 1. Characterization of the iPSC line PCCB10-FiPS4F1 (UAMi004-A).

in either the *PCCA* or *PCCB* genes, encoding both subunits of the mitochondrial propionyl-CoA carboxylase (PCC) enzyme, that catalyzes the carboxylation of propionyl-CoA to D-methylmalonyl-CoA, which eventually enters the Krebs cycle as succinyl-CoA (Richard et al., 2015). Fibroblasts from a homozygous PA patient carrying the previously described c.1218\_1231del14ins12 (p.G407 fs) mutation in the *PCCB* gene (Tahara et al., 1990) were reprogrammed using the CytoTune™ iPS Reprogramming kit delivering the four human reprogramming factors *OCT3/4*, *SOX2*, *c-MYC* and *KLF4* (Takahashi et al., 2007). The iPSC line PCCB10-FiPS4F1 (UAMi004-A) (PCCB10–1 in figures for short) displayed a typical round shape ESC-like morphology and growth behaviour on feeder layers and on feeder-free layers (Fig. 1A, Table 1). Clearance of the vectors and of the exogenous reprogramming factor genes was observed by RT-PCR after 8 culture passages (Fig. 1B). Expression of key pluripotency genes was observed at protein level by immunocytochemistry (transcription factors OCT4, NANOG and SOX2, and surface markers SSEA-3, SSEA-4, TRA-1-60 and TRA-1-81) (Fig. 1C, Table 1) and flow cytometry analysis (Fig. 1D, Table 1). The iPSC line displayed a normal karyotype (46, XX) after more than twenty culture passages (Fig. 1E). The cells had the capacity to form derivatives of all three germ layers (endoderm, mesoderm and ectoderm) upon embryoid body differentiation (Fig. 1F, Table 1). Mycoplasma testing by PCR revealed a negative result (Supplementary Fig. S1A). We confirmed the presence of the mutation in the iPSC line in homozygous fashion by Sanger sequencing (Supplementary Fig. S1B); and we also confirmed by DNA fingerprinting analysis that the line was derived from the patient fibroblasts.

### 3. Materials and methods

#### 3.1. Non-integrative reprogramming of mutant *PCCB* fibroblasts into iPSC

The present study included available fibroblasts from a PA patient with defects in the *PCCB* gene. Experimental protocols were approved by the Institutional Ethical Committee of the Universidad Autónoma de Madrid according to Spanish and European Union legislation, and the informed consent was obtained from the legal care-givers. Fibroblasts were reprogrammed using the CytoTune™ iPS Reprogramming kit (ThermoFisher Scientific) following the manufacturer's instructions. iPSCs were maintained and expanded both on feeder layers and on feeder-free layers as previously described (Alonso-Barroso et al., 2017).

#### 3.2. Detection of Sendai virus genome and transgenes

After 8 passages, iPSC line was tested for Sendai virus (SeV) residues as described (Alonso-Barroso et al., 2017). PCR was performed using the primers indicated in Table 2 and following the instructions as

recommended by the manufacturer. In Fig. 1 panel B: C+: transduced cell pool at passage zero; C–: non-template control.

#### 3.3. Immunofluorescence analysis

iPSC were grown on feeder-free layers on 15  $\mu$ -Slide 8 well culture plates (Ibidi) and fixed with Formaline Solution 10% (Sigma-Aldrich). Immunofluorescence analysis was performed as previously described (Alonso-Barroso et al., 2017). In Fig. 1 scale bars: 100  $\mu$ m.

#### 3.4. Flow cytometry analysis

We analysed the pluripotency-associated markers SSEA-3 and SSEA-4 by flow cytometry as described (Alonso-Barroso et al., 2017). Unstained iPSCs and the corresponding isotype antibodies were used as negative controls to exclude data from non-specific fluorescence.

#### 3.5. In vitro differentiation

iPSCs were detached with Accutase™ into a single cell suspension and resuspended in mTESR™1 medium (StemCell™ Technologies) with 10  $\mu$ M Rock inhibitor (StemCell™ Technologies). Embryoid body formation was induced by seeding 20,000–30,000 iPSC cells in 120  $\mu$ l of mTESR™1 medium in each well of 96-well v-bottom, low attachment plates (Deltalab). *In vitro* differentiation was performed as described (Alonso-Barroso et al., 2017).

#### 3.6. Mycoplasma detection

Cells were screened for mycoplasma contamination by PCR (Uphoff & Drexler, 2014). A positive sample with mycoplasma was used as a control. In Supplementary Fig. S1A: positive control (C+).

#### 3.7. Mutation analysis

Genomic DNA from patient-derived fibroblasts and iPSCs was isolated using MagNA Pure Compact DNA Isolation kit and MagNA Pure Compact instrument (Roche). Subsequently, amplification by PCR of the *PCCB* region containing the mutation was carried out using the primers indicated in Table 2, FastStart Taq DNA Polymerase (Roche), the Veriti Thermal Cycler (ThermoFisher Scientific) and the PCR program: 94 °C 5 min; 94 °C 25 s, 55 °C 25 s and 72 °C 40 s for 38 cycles; and 72 °C 7 min. Amplified PCR fragments were sequenced in an ABI3730 sequencer (Applied Biosystems).

**Table 1**  
Characterization and validation.

Classification	Test	Result	Data
Morphology	Photography	Normal	Fig. 1 panel A
Phenotype	Qualitative analysis (Immunocytochemistry)	Positive for: OCT4, NANOG, SOX2, SSEA-3, TRA-1-81, SSEA-4 and TRA-1-60	Fig. 1 panel C
	Quantitative analysis (Flow cytometry)	SSEA-3 and SSEA-4: 95%	Fig. 1 panel D
	Karyotype (G-banding) and resolution	46XX Resolution 450–500	Fig. 1 panel E
Identity	STR analysis	16 sites tested and all of them matched	Available with the authors
Mutation analysis (IF APPLICABLE)	Sequencing	c.1218_1231del14ins12 (p.G407fs)	Supplementary Fig. S1 panel B
Microbiology and virology	Southern Blot OR WGS	Not performed	
	Mycoplasma	Mycoplasma testing by PCR: negative	Supplementary Fig. S1 panel A
Differentiation potential	Embryoid body formation	Expression of $\alpha$ -1-fetoprotein (endoderm), $\alpha$ -smooth muscle actin (mesoderm) and $\beta$ -III-tubulin Tuj1 (ectoderm)	Fig. 1 panel F
Donor screening (OPTIONAL)	HIV 1 + 2 Hepatitis B, Hepatitis C	Not performed	No
Genotype additional info (OPTIONAL)	Blood group genotyping	Not performed	No
	HLA tissue typing	Not performed	No

**Table 2**  
Reagents details.

Antibodies used for immunocytochemistry/flow-cytometry			
	Antibody	Dilution	Company Cat # and RRID
Pluripotency Markers	Mouse IgG anti-OCT4	1:60	Santa Cruz Cat# sc-5279, AB_628051
	Rat IgM anti-SSEA-3	1:3	Hybridoma Bank Cat# MC-631, AB_528476
	Rabbit IgG anti-SOX2	1:100	Fisher Thermo Scientific Cat# PA1-16968, AB_2195781
	Mouse IgG anti-SSEA-4	1:3	Hybridoma Bank Cat# MC-813-70, AB_528477
	Mouse IgM anti-TRA-1-60	1:200	Millipore Cat# MAB4360, AB_2119183
	Goat IgG anti-NANOG human	1:25	R&D Cat# AF1997, AB_355097
Differentiation Markers	Mouse IgM anti-TRA-1-81	1:200	Millipore Cat# MAB4381, AB_177638
	Rabbit IgG anti- $\alpha$ -Fetoprotein	1:400	Dako Cat# A0008, AB_2650473
	Mouse IgG anti- $\beta$ -III-Tubulin Tuj1	1:500	Covance Cat# MMS-435P, AB_231377
	Mouse IgG anti- $\alpha$ -smooth muscle actin	1:400	Sigma-Aldrich Cat# A5228, AB_262054
Secondary antibodies	Alexa 555 Donkey anti-Mouse IgG	1:200	Thermo Fischer Cat# A-31570, AB_2536180
	Alexa 488 Goat anti-Rat IgM	1:200	Thermo Fischer Cat#A-21212, AB_2535798
	Alexa 488 Donkey anti-Rabbit IgG	1:200	Thermo Fischer Cat# A-31572, AB_162543
	Alexa 555 Donkey anti-Mouse IgG	1:200	Thermo Fischer Cat# A-31570, AB_2536180
	Alexa 647 Goat anti-Mouse IgM	1:200	Thermo Fischer Cat# A-21238, AB_2535807
	Alexa 647 Donkey anti-Goat IgG	1:200	Thermo Fischer Cat# A-21447, AB_2535864
	Cy3 Donkey anti-Mouse IgM	1:200	Jackson Cat# 715-165-140, AB_2340812
	Alexa 647 Goat anti-mouse IgG	1:600	Thermo Fischer Cat# A- 21235, AB_2535804
	Alexa 647 Donkey anti-rat IgM	1:600	Thermo Fischer Cat# A-21248, AB_2535816
Primers			
	Target	Forward/Reverse primer (5'-3')	
Reverse Transcription-PCR	<i>SeV</i> genome (181 pb)	GGATCACTAGGTGATATCGAGC/ ACCAGACAAGAGTTAAGATATGTATC	
	<i>KOS</i> transgene (528 bp)	ATGCACCGCTACGACGTGAGCGC/ ACCTTGACAATCCTGATGTGG	
	<i>KLF4</i> transgene (410 bp)	TTCTGTCATGCCAGAGGAGCC/ AATGTATCGAAGGTGCTCAA	
	<i>c-MYC</i> transgene (532 bp)	TAACCTGACTAGCAGGCTTGTCG/ TCCACATACAGTCTGGATGATGATG	
Targeted mutation analysis/sequencing (PCR)	<i>PCCB-exons 11 and 12</i> (601 bp)	GGATGGCTGCTGAGGACAAA/TCCACCACGGCTATGCTGTAG	
Mycoplasma detection (PCR)	Mycoplasma species (986 bp: internal control band; and 520 bp: mycoplasma specific band)	Forward primers: CGCCTGAGTACGTTCGC CGCCTGAGTACGTACGC TGCCTGGGTAGTACATTCCG TGCCTGAGTAGTACATTCCG CGCCTGAGTAGTATGCTCGC CACCTGAGTAGTATGCTCGC CGCCTGGGTAGTACATTCCG Reverse primers: GCGGTGTGTACAAGACCCGA GCGGTGTGTACAAAACCCGA GCGGTGTGTACAACCCCGA	

### 3.8. Karyotype analysis

Karyotype analysis of the iPSC line was carried out using cells with more than twenty culture passages which were processed using standard cytogenetic techniques as described (Alonso-Barroso et al., 2017). At least 35 metaphases were karyotyped.

### 3.9. DNA fingerprinting analysis

DNA fingerprinting analysis was performed as previously described (Alonso-Barroso et al., 2017).

Supplementary data to this article can be found online at <https://doi.org/10.1016/j.scr.2019.101469>.

### Acknowledgments

Research reported in this work was funded by Grant PAF107 from the Propionic Acidemia Foundation and by grant SAF2016-76004-R from Spanish Ministry of Economy and Competitiveness and European Regional Development Fund. The authors thank INDEPF (Instituto de investigación y desarrollo social de enfermedades poco frecuentes), the Cytogenetic unit from Centro Nacional de Investigaciones Oncológicas

(CNIO) and Mar Álvarez for their excellent technical assistance. *Centro de Biología Molecular Severo Ochoa* receives an institutional grant from *Fundación Ramón Areces*. ALM is a postdoctoral researcher of Comunidad Autónoma de Madrid (PEJD-2017-POST/BMD-3671). EAB is a PhD student funded by the FPU program of the Spanish Ministry of Science, Innovation and Universities (FPU15/02923).

### References

- Alonso-Barroso, E., Brasil, S., Briso-Montiano, A., Navarrete, R., Perez-Cerda, C., Ugarte, M., Perez, B., Desviat, L.R., Richard, E., 2017. Generation and characterization of a human iPSC line from a patient with propionic acidemia due to defects in the PCCA gene. *Stem Cell Res.* 23, 173–177.
- Richard, E., Perez, B., Perez-Cerda, C., Desviat, L.R., 2015. Understanding molecular mechanisms in propionic acidemia and investigated therapeutic strategies. *Expert Opin on Orphan Drugs* 3, 1427–1438.
- Tahara, T., Kraus, J.P., Rosenberg, L.E., 1990. An unusual insertion/deletion in the gene encoding the  $\beta$ -subunit of propionyl-CoA carboxylase is a frequent mutation in Caucasian propionic acidemia. *Proc. Natl. Acad. Sci. U. S. A.* 87, 1372–1376.
- Takahashi, K., Tanabe, K., Ohnuki, M., Narita, M., Ichisaka, T., Tomoda, K., Yamanaka, S., 2007. Induction of pluripotent stem cells from adult human fibroblasts by defined factors. *Cell* 131, 861–872.
- Uphoff, C.C., Drexler, H.G., 2014. Detection of mycoplasma contamination in cell cultures. *Curr Protoc Mol Biol* 106, 28.4.1–28.4.14.





## Corrigendum

## Corrigendum to “Generation and characterization of a human iPSC line (UAMi004-A) from a patient with propionic acidemia due to defects in the PCCB gene” [Stem Cell Research, Volume 38, July 2019, 101469]



Arístides López-Márquez<sup>a</sup>, Esmeralda Alonso-Barroso<sup>a,b,c,d</sup>, Gema Cerro-Tello<sup>a</sup>, Irene Bravo-Alonso<sup>a,b,c,d</sup>, Laura Arribas-Carreira<sup>a,b,c,d</sup>, Álvaro Briso-Montiano<sup>a,b,c,d</sup>, Rosa Navarrete<sup>b,c,d</sup>, Celia Pérez-Cerdá<sup>b,c,d</sup>, Magdalena Ugarte<sup>b,c,d</sup>, Belén Pérez<sup>a,b,c,d</sup>, Lourdes R. Desviat<sup>a,b,c,d</sup>, Eva Richard<sup>a,b,c,d,\*</sup>

<sup>a</sup> Centro de Biología Molecular Severo Ochoa UAM-CSIC, Universidad Autónoma de Madrid, Madrid, Spain

<sup>b</sup> Centro de Diagnóstico de Enfermedades Moleculares (CEDEM), Madrid, Spain

<sup>c</sup> Centro de Investigación Biomédica en Red de Enfermedades Raras (CIBERER), ISCIII, Madrid, Spain

<sup>d</sup> Instituto de Investigación Sanitaria Hospital La Paz (IdiPaz), ISCIII, Madrid, Spain

The authors regret that the karyotype figure was incorrect. A corrected version of the figure is provided below. 35 metaphases of the iPSC line were analysed and no abnormalities were detected.



The authors would like to apologise for any inconvenience caused.

DOI of original article: <https://doi.org/10.1016/j.scr.2019.101469>

\* Corresponding author at: Centro de Biología Molecular Severo Ochoa UAM-CSIC, Nicolás Cabrera 1, Universidad Autónoma Madrid, 28049 Madrid, Spain.  
E-mail address: [erichard@cbm.csic.es](mailto:erichard@cbm.csic.es) (E. Richard).

<https://doi.org/10.1016/j.scr.2019.101513>

CYTOGENETIC REPORT: 19CG0159

---

**Case details:**

**Sample Name:** PCCB-iPSC

**Specimen type:** iPS cells on Matrigel

**Date of sample:** 02/27/2019

**Referring Lab:** CBM "Severo Ochoa"

**Referring Physician:** Dr Eva Richard

**Date completed:** 03/20/2019

**Completed by:** Francisco J Moya

**Reviewed and interpreted by:** Sandra Rodriguez-Perales, PhD

**Indication for study:** Chromosomal analysis of human iPS cells

**Test performed:** Chromosome analysis (G-banding)

---

**ISCN 2016 Result:** 46,XX

**Result:** Normal female karyotype

---

**Interpretation:**


A total of 35 metaphases from iPS cell culture have been analysed. No abnormalities were detected at the stated band level of resolution. The standard cytogenetic methodology utilized in this analysis does not routinely detect small rearrangements and small copy number variations (CNVs).

Cell: 20  
Slide: 3  
Case: 19CG0159  
# of cells karyotyped: 35  
Band resolution: 300-400



# Línea PCCB10-FiPS4F-1

## Actividad fosfatasa alcalina (FA)



## STR análisis

Marker	Fibroblasts		PCCB10-1	
	Size (Allele)		Size (Allele)	
D8S1179	155 (15)	155 (15)	155 (15)	155 (15)
D21S11	197 (27)	205 (29)	197 (27)	205 (29)
D7S820	268 (9)	272 (10)	268 (9)	272 (10)
CSF1PO	328 (12)	328 (12)	328 (12)	328 (12)
D3S1358	130 (16)	134 (17)	130 (16)	134 (17)
TH01	180 (8)	187 (9.3)	180 (8)	187 (9.3)
D13S317	218 (8)	234 (12)	218 (8)	234 (12)
D16S539	277 (11)	281 (12)	277 (11)	281 (12)
D2S1338	312 (16)	328 (20)	312 (16)	328 (20)
D19S433	122 (14)	122 (14)	122 (14)	122 (14)
vWA	172 (15)	172 (15)	172 (15)	172 (15)
TPOX	235 (9)	243 (11)	235 (9)	243 (11)
D18S51	289 (13)	297 (15)	289 (13)	297 (15)
D5S818	153 (11)	157 (12)	153 (11)	157 (12)
FGA	233 (21)	241 (23)	233 (21)	241 (23)
Amelogenin	107 (X)	107 (X)	107 (X)	107 (X)